Business Wire

MN-VÄRDE-PARTNERS

14.1.2021 14:02:39 CET | Business Wire | Press release

Share
Värde Names New Partner and Senior Managing Directors

Värde Partners, a leading global alternative investment firm, is pleased to announce that Brendan Albee has been promoted to Partner.

“Over the past six years, Brendan has demonstrated strong leadership and character while driving advances in scaling our world-class global operations and infrastructure. His direction and forethought have proven instrumental to the growth and success of the firm in many ways, not least of which includes ensuring Värde was well prepared with the technology and systems for a seamless transition to remote work in 2020. We are excited to welcome him as a partner,” said George Hicks, Värde Co-Founder and Co-CEO, and Ilfryn Carstairs, Co-CEO and CIO.

Brendan joined Värde in 2014 to serve as the firm’s Chief Operating Officer with global responsibility for the accounting, treasury, valuations, operations and technology functions. Based in Minneapolis, he is a member of the firm’s Investment Committee, Senior Leadership Committee, and Operating Committee. He is also active in the firm’s fund and product development as well as enterprise risk management.

Prior to joining Värde, Brendan served as global COO for the Alternative Asset Management, Equities, Structured Products, Asset Servicing and Securities Operations teams at Barclays Bank. Prior to Barclays, Brendan spent more than a decade in various roles within audit, investment banking, and strategy at JPMorgan Chase.

Alongside Brendan’s appointment, Värde announced two promotions to Senior Managing Director:

  • Ria Nova, Head of Americas Business Development and Investor Relations, also oversees the firm’s consultant, intermediary and product specialist efforts. Based in New York, she joined the firm in 2017.
  • Michael Reimler, Global Head of Finance, is responsible for leading and managing the accounting and financial reporting for Vӓrde’s investment funds, general partner entities and management companies, and for leading and managing the firm’s Treasury function. Based in Minneapolis, he joined the firm in 2010.

In addition, Värde recently hired Monty Cook as Head of Financial Services, North America. Based in New York, Monty leads the firm’s investing in financial services assets across North America with a focus on private credit investments in traditional and emerging asset classes. He reports to Aneek Mamik, Global Co-Head of Financial Services.

“We’re pleased to welcome Monty at an exciting time for the financial services team,” said Aneek. “Leveraging Monty’s tremendous industry experience and the strength of Värde’s platform, we are pleased to be expanding our lending solutions for the financial services sector and building on the firm’s capabilities to deliver value for investors.”

Monty joins Värde from First Eagle Alternative Credit, where he served as Head of Financial Services. Monty was with THL Credit for seven years before it was acquired by First Eagle and most recently served as Co-Head of Direct Lending. Prior to THL Credit, Monty was a Director in Deutsche Bank’s Credit Solutions Group where he sourced and structured credit investments across numerous specialty finance and other asset classes.

About Värde Partners:

Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye